NP
Elite in Desmoid Tumor

Nicolas P. Penel

Centre Oscar Lambret
France
Elite
 in Desmoid Tumor
Clinical Trials:Currently Recruiting for 10 Trials
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Nicolas P. Penel's experience treating your condition:
About Nicolas P. Penel

Nicolas Penel practices in Lille Cedex, France. Penel is rated as an Elite expert by MediFind in the treatment of Desmoid Tumor. He is also highly rated in 34 other conditions, according to our data. His top areas of expertise are Fibromatosis, Desmoid Tumor, Angiosarcoma, Hysterectomy, and Orchiectomy.

His clinical research consists of co-authoring 370 peer reviewed articles and participating in 29 clinical trials in the past 15 years. In particular, he has co-authored 24 articles and participated in 2 clinical trials in the study of Desmoid Tumor.

Locations
Lille Cedex, FR
Background & Education
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: November 02, 2022
Intervention Type: Genetic
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drugs: Association atezolizumabBDB001
Study Phase: Phase 2
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Enrollment Status: Recruiting
Publish Date: April 04, 2022
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Enrollment Status: Recruiting
Publish Date: March 29, 2022
Intervention Type: Combination Product
Study Drug: Atezolizumab
Study Phase: Phase 2
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
Enrollment Status: Recruiting
Publish Date: December 29, 2021
Intervention Type: Genetic
Study Phase: Not Applicable
Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers
Enrollment Status: Recruiting
Publish Date: October 13, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
Enrollment Status: Recruiting
Publish Date: August 02, 2021
Intervention Type: Other
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Enrollment Status: Recruiting
Publish Date: July 29, 2021
Intervention Type: Drug
Study Drug: Imatinib Maintenance
Study Phase: Phase 3
Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment
Enrollment Status: Recruiting
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Recruiting
Publish Date: December 09, 2020
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Enrollment Status: Active, not recruiting
Publish Date: November 29, 2022
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: AvapritinibRegorafenib
Study Phase: Phase 3
Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
Enrollment Status: Not yet recruiting
Publish Date: August 15, 2022
Intervention Type: Other
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: OlaratumabGemcitabineDocetaxel
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues Collected for Two Age Groups.
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis
Enrollment Status: Active, not recruiting
Publish Date: May 13, 2021
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Enrollment Status: Active, not recruiting
Publish Date: May 05, 2021
Intervention Type: Drug
Study Drugs: MK3475PembrolizumabEndoxanCyclophosphamideG100Metronomic
Study Phase: Phase 2
Multicentre, Open-label Phase 2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Enrollment Status: Terminated
Publish Date: April 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: December 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma
Enrollment Status: Completed
Publish Date: September 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle
Enrollment Status: Completed
Publish Date: May 31, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.
Enrollment Status: Completed
Publish Date: May 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT
Enrollment Status: Unknown status
Publish Date: August 08, 2018
Intervention Type: Drug
Study Drug: Chemotherapy
Study Phase: Phase 2
Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide
Enrollment Status: Completed
Publish Date: July 29, 2016
Intervention Type: Drug, Biological
Study Phase: Phase 1
Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma: Chest Radiograph Versus Chest CT
Enrollment Status: Terminated
Publish Date: July 29, 2016
Intervention Type: Procedure
Study Phase: Phase 2
Crossed Assessment of the Burden Within the Dyad Patient/Caregiver: Analysis of Explanatory Factors and Consequences for Return at Home of the Life-ending Patient
Enrollment Status: Completed
Publish Date: July 23, 2012
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery
Enrollment Status: Unknown status
Publish Date: December 24, 2009
Intervention Type: Drug
Study Phase: Phase 2
View 19 Less Clinical Trials -
370 Total Publications
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 14, 2022
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more